This is a working overview of hGH fragment, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-11-15 and is reviewed periodically as new material appears.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form |
| Solubility | Soluble in water | Also soluble in aqueous buffers |
| Storage temperature | -20°C or below | Protect from light and moisture |
| Analytical method | RP-HPLC | Purity and identity assessment |
| Mass confirmation | Mass spectrometry | Verifies molecular mass |
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
This deposit is blue naturally and turns green when heated due to dehydration. It is restricted to a mine-riddled region in Nishapur, the 2,012 m (6,601 ft) mountain peak of Ali-mersai near Mashhad, the capital of Khorasan Province, Iran. Weathered and broken trachyte is host to the turquoise, which is found both in situ between layers of limonite and sandstone and amongst the scree at the mountain's base. These workings are the oldest known, together with those of the Sinai Peninsula. Iran also has turquoise mines in Semnan and Kerman provinces.
=== Differential diagnosis === 6-phosphogluconate dehydrogenase (6PGD) deficiency has similar symptoms and is often mistaken for G6PD deficiency, as the affected enzyme is within the same pathway; however, these diseases are not linked and can be found within the same person.
As all 19 hijackers died in the attacks, they were never prosecuted. Osama bin Laden was never formally indicted; he was ultimately killed by U.S. special operations forces on May 2, 2011, in his compound in Abbottabad, Pakistan, after a 10-year manhunt. The main trial of the attacks against Mohammed and his co-conspirators Walid bin Attash, Ramzi bin al-Shibh, Ammar al-Baluchi, and Mustafa Ahmad al-Hawsawi remains unresolved. Khalid Sheikh Mohammed was arrested on March 1, 2003, in Rawalpindi, Pakistan, by Pakistani security officials working with the CIA. He was then held at multiple CIA secret prisons and Guantanamo Bay detention camp, where he was interrogated and tortured with methods including waterboarding. In 2003, al-Hawsawi and Abd al-Aziz Ali were arrested and transferred to U.S. custody. Both would later be accused of providing money and travel assistance to the hijackers. During U.S. hearings at Guantanamo Bay in March 2007, Mohammed again confessed his responsibility for the attacks, stating he "was responsible for the 9/11 operation from A to Z" and that his statement was not made under duress. In January 2023, the U.S. government opened up about a potential plea deal, with Biden giving up on the effort in September that year. To date, only peripheral persons have thus been convicted for charges in connection with the attacks. These include:
Sources: en.wikipedia.org
In a speech to the Scottish Labour Party conference in Edinburgh, Labour leader Sir Keir Starmer rules out a deal with the SNP "under any circumstances", and warns against complacency following the departure of Nicola Sturgeon as SNP leader and First Minister. 20 February – Finance Secretary Kate Forbes announces she is running in the Scottish National Party leadership election. 21 February Kate Forbes insists her campaign to become the next SNP leader has not been derailed after she lost the support of several colleagues following comments about same-sex marriage and having children outside marriage, both of which she is opposed to as a member of the Free Church of Scotland. MSPs vote 68–57 to approve the Scottish Government's budget for the 2023–24 financial year, which includes a tax rise for everyone in Scotland earning more than £43,662. 23 February – Sir Iain Livingstone announces he will retire as Chief Constable of Police Scotland in the summer after five years in the post. 24 February Nominations close for the SNP leadership election, with Kate Forbes, Ash Regan and Humza Yousaf having all reached the threshold of supporters to go forward into the contest. Two crew died after tugboat capsized & sank close to Greenock harbour. 25 February – Members of the Scottish Secondary Teachers' Association (SSTA) vote to accept a new pay offer from the Scottish Government, and announce they have suspended strike action scheduled for the following week. 28 February – Transgender rapist Isla Bryson is sentenced to eight years in prison with a further three years supervision.
=== Aircraft === C-4, the US Army designation of the Ford Trimotor AEG C.IV, a German World War I reconnaissance aircraft AGO C.IV, a 1917 German reconnaissance aircraft C-4 Academe, the military version of Gulfstream I twin turboprop business aircraft C-4 Argonaut, a Canadair aircraft derived from the Douglas DC-4 Cierva C.4, a 1922 Spanish experimental autogyro DFW C.IV, a 1916 German reconnaissance aircraft Flight Design C4, a four-seat light aircraft Fokker C.IV, a 1923 Dutch two-seat reconnaissance aircraft Rumpler C.IV, a 1917 German single-engine, two-seater reconnaissance biplane
The use of X-rays for diagnostic purposes in dentistry was made possible by the pioneering work of C. Edmund Kells (1856-1928), a New Orleans dentist who demonstrated them to dentists in Asheville, North Carolina, in July 1896. Kells committed suicide after suffering from radiation-induced cancer for many years. He had been amputated one finger at a time, later his entire hand, followed by his forearm and then his entire arm. Otto Walkhoff (1860-1934), one of the most important German dentists in history, took X-rays of himself in 1896 and is considered a pioneer in dental radiology. He described the required exposure time of 25 minutes as an "ordeal". Braunschweig's medical community later commissioned him to set up and supervise a central X-ray facility. In 1898, the year radium was discovered, he also tested the use of radium in medicine in a self-experiment using an amount of 0.2 grams of radium bromide. Walkhoff observed that cancerous mice exposed to radium radiation died significantly later than a control group of untreated mice. He thus initiated the development of radiation research for the treatment of tumors.
Sources: en.wikipedia.org
Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.
Lyophilized powder should be stored at -20°C or lower, protected from light and moisture. Reconstituted solutions are less stable and should be aliquoted to avoid freeze-thaw cycles. Always follow supplier instructions.
Variability in purity, counterion content, and residual solvents is possible. Independent testing and certificates of analysis help verify quality. Microbial contamination can occur if handling is not sterile.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.